摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-methanesulfonylcyclohex-1-en-1-yl trifluoromethanesulfonate | 862129-73-5

中文名称
——
中文别名
——
英文名称
4-methanesulfonylcyclohex-1-en-1-yl trifluoromethanesulfonate
英文别名
4-methylsulfonylcyclohex-1-ene-1-yl trifluoromethanesulfonate;(+/-)-trifluoro-methanesulfonic acid 4-methanesulfonyl-cyclohex-1-enyl ester;(+/-)-Trifluoro-methanesulfonic acid 4-methanesulfonyl-cyclohex-1-enyl ester;(4-methylsulfonylcyclohexen-1-yl) trifluoromethanesulfonate
4-methanesulfonylcyclohex-1-en-1-yl trifluoromethanesulfonate化学式
CAS
862129-73-5
化学式
C8H11F3O5S2
mdl
——
分子量
308.3
InChiKey
JXYRYNVITOGWLN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    428.4±45.0 °C(Predicted)
  • 密度:
    1.55±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    18
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.75
  • 拓扑面积:
    94.3
  • 氢给体数:
    0
  • 氢受体数:
    8

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] SELECTIVE ESTROGEN RECEPTOR MODULATORS<br/>[FR] MODULATEURS SELECTIFS DU RECEPTEUR DES OESTROGENES
    申请人:LILLY CO ELI
    公开号:WO2005073206A1
    公开(公告)日:2005-08-11
    The present invention relates to a selective estrogen receptor modulator of formula I: or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and uterine leiomyoma.
    本发明涉及式I的选择性雌激素受体调节剂:或其药物酸加成盐;例如,用于治疗子宫内膜异位症和子宫肌瘤。
  • Selective estrogen receptor modulators
    申请人:Dodge Alan Jeffrey
    公开号:US20070066595A1
    公开(公告)日:2007-03-22
    The present invention relates to a selective estrogen receptor modulator of formula I: or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and uterine leiomyoma.
    本发明涉及一种I式的选择性雌激素受体调节剂或其药物酸盐,可用于治疗子宫内膜异位症和子宫平滑肌瘤等疾病。
  • EP300/CBP MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF
    申请人:Miracure Biotechnology Limited
    公开号:US20240109868A1
    公开(公告)日:2024-04-04
    The present disclosure relates to an EP300/CBP modulator represented by formula I, a preparation method therefor and use thereof. The structure of formula I is shown below:
  • Structure–activity relationships of SERMs optimized for uterine antagonism and ovarian safety
    作者:Timothy I. Richardson、Scott A. Frank、Minmin Wang、Christian A. Clarke、Scott A. Jones、Bai-Ping Ying、Dan T. Kohlman、Owen B. Wallace、Timothy A. Shepherd、Robert D. Dally、Alan D. Palkowitz、Andrew G. Geiser、Henry U. Bryant、Judith W. Henck、Ilene R. Cohen、Daniel G. Rudmann、Denis J. McCann、David E. Coutant、Samuel W. Oldham、Conrad W. Hummel、Kin C. Fong、Ronald Hinklin、George Lewis、Hongqi Tian、Jeffrey A. Dodge
    DOI:10.1016/j.bmcl.2007.04.044
    日期:2007.7
    Structure-activity relationship studies are described, which led to the discovery of novel selective estrogen receptor modulators (SERMs) for the potential treatment of uterine fibroids. The SAR studies focused on limiting brain exposure and were guided by computational properties. Compounds with limited impact on the HPO axis were selected using serum estrogen levels as a biomarker for ovarian stimulation. (c) 2007 Elsevier Ltd. All rights reserved.
查看更多